Compare Amylx Pharmaceuticals Inc (AMLX) vs Entegris Inc (ENTG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Entegris Inc — how do they compare? Amylx Pharmaceuticals Inc trades at $17.77 (market cap $1.98B), while Entegris Inc trades at $141.29 (market cap $22.14B). The key difference: Entegris Inc is far larger — about 11.2× Amylx Pharmaceuticals Inc's market cap, and Entegris Inc pays a 0.28% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | ENTG | |
|---|---|---|
Market Cap | $1.98B | $22.14B |
Sector | Health | Technology |
52-Week High | $18.70 | $184.00 |
52-Week Low | $7.64 | $68.80 |
Enterprise Value | $1.70B | $25.45B |
Dividend Yield | — | 0.28% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
ENTG trades at $145.35, down 0.51% today, with technical indicators showing a bearish trend and support at $143. The company reported Q1 2026 EPS of $0.86, beating estimates, but maintains premium valuations with a P/E of 84.02. Revenue has been stable around $3.2B annually, with net income margins improving to 8.18% in 2026. Analyst sentiment remains positive with a $178.40 price target, though recent news highlights volatility and valuation concerns.
Outlook: ENTG benefits from semiconductor industry tailwinds and AI-driven demand, but faces risks from high valuation and market volatility. The stock offers potential upside based on analyst targets, but investors should monitor earnings consistency and competitive pressures in the tech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Entegris Inc
Entegris Inc is a supplier of advanced materials and process solutions for the semiconductor and other high-technology industries. The company's reportable segments include Specialty Chemicals & Engineered Materials (SCEM), Microcontamination Control (MC), and Advanced Materials Handling (AMH). The SCEM segment provides high-performance & high-purity process chemistries, gases, & materials, and safe & efficient delivery systems. The Microcontamination Control (MC) segment includes solutions to purify critical liquid chemistries and process gases used in semiconductor manufacturing processes and other high-technology industries. Its geographical segments are Taiwan, North America, South Korea, Japan, China, Europe, and Southeast Asia.
Read more on ENTG →
